{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T06:35:31Z","timestamp":1770705331218,"version":"3.49.0"},"reference-count":31,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,7,3]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To conduct a cost-effectiveness analysis from the perspective of the Spanish National Health System (NHS) comparing ixekizumab versus secukinumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A Markov model with a lifetime horizon and monthly cycles was developed based on the York model. Four health states were included: a biological disease-modifying antirheumatic drug (bDMARD) induction period of 12 or 16\u2009weeks, maintenance therapy, best supportive care (BSC) and death. Treatment response was assessed based on both Psoriatic Arthritis Response Criteria (PsARC) and \u226590% improvement in the Psoriasis Area Severity Index score (PASI90). At the end of the induction period, responders transitioned to maintenance therapy. Non-responders and patients who discontinued maintenance therapy transitioned to BSC. Clinical efficacy data were derived from a network meta-analysis. Health utilities were generated by applying a regression analysis to Psoriasis Area Severity Index and Health Assessment Questionnaire\u2012Disability Index scores collected in the ixekizumab SPIRIT studies. Results were subject to extensive sensitivity and scenario analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Spanish NHS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>A hypothetical cohort of bDMARD-na\u00efve patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis was modelled.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>Ixekizumab and secukinumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ixekizumab performed favourably over secukinumab in the base-case analysis, although cost savings and quality-adjusted life-year (QALY) gains were modest. Total costs were \u20ac153\u2009901 compared with \u20ac156\u2009559 for secukinumab (difference \u2212\u20ac2658). Total QALYs were 9.175 vs 9.082 (difference 0.093). Base-case results were most sensitive to the annual bDMARD discontinuation rate and the modification of PsARC and PASI90 response to ixekizumab or secukinumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Ixekizumab provided more QALYs at a lower cost than secukinumab, with differences being on a relatively small scale. Sensitivity analysis showed that base-case results were generally robust to changes in most input parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>SPIRIT-P1: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial post-results\" xlink:href=\"NCT01695239\">NCT01695239<\/jats:ext-link>; Post-results, SPIRIT-P2: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial post-results\" xlink:href=\"NCT02349295\">NCT02349295<\/jats:ext-link>; Post-results.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-032552","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T10:00:30Z","timestamp":1597399230000},"page":"e032552","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct01695239","registry":"10.18810\/clinical-trials-gov","type":"postResults"},{"clinical-trial-number":"nct02349295","registry":"10.18810\/clinical-trials-gov","type":"postResults"}],"author":[{"given":"Bernd","family":"Schweikert","sequence":"first","affiliation":[{"name":"Real World Evidence Strategy and Analytics, Commercialisation and Outcomes, ICON, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Malmberg","sequence":"additional","affiliation":[{"name":"Access, Commercialisation and Communications, ICON, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2675-0945","authenticated-orcid":false,"given":"Mercedes","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"name":"Health Outcomes and Real World Evidence, Eli Lilly and Company, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Dilla","sequence":"additional","affiliation":[{"name":"Global Patient Outcomes and Real World Evidence International, Eli Lilly and Company, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Sapin","sequence":"additional","affiliation":[{"name":"European Statistics, Eli Lilly and Company, Neuilly-sur-Seine, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Hartz","sequence":"additional","affiliation":[{"name":"Global Patient Outcomes and Real World Evidence International, Eli Lilly and Company, Windlesham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"2025101811050173000_10.8.e032552.1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12016-017-8630-7","article-title":"Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs","volume":"55","author":"McArdle","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025101811050173000_10.8.e032552.2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/annrheumdis-2018-eular.6463","article-title":"THU0684 Prevalence of rheumatic diseases in adult population in Spain. Episer 2016 study","volume":"77","author":"Seoane-Mato","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025101811050173000_10.8.e032552.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025101811050173000_10.8.e032552.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08148.x"},{"key":"2025101811050173000_10.8.e032552.5","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0618-5"},{"key":"2025101811050173000_10.8.e032552.6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1586\/14737167.2015.965154","article-title":"The indirect costs of psoriatic arthritis: systematic review and meta-analysis","volume":"15","author":"Kawalec","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025101811050173000_10.8.e032552.7","unstructured":"European Medicines Agency . Ixekizumab (Taltz): summary of product characteristics, 2016. Available: www.ema.europa.eu\/documents\/product-information\/taltz-epar-product-information_en.pdf [Accessed 22 Mar 2019]."},{"key":"2025101811050173000_10.8.e032552.8","unstructured":"European Medicines Agency . Secukinumab (Cosentyx): summary of product characteristics, 2015. Available: www.ema.europa.eu\/documents\/product-information\/cosentyx-epar-product-information_en.pdf [Accessed 22 Mar 2019]."},{"key":"2025101811050173000_10.8.e032552.9","doi-asserted-by":"publisher","DOI":"10.3310\/hta10200"},{"key":"2025101811050173000_10.8.e032552.10","doi-asserted-by":"publisher","DOI":"10.3310\/hta15140"},{"key":"2025101811050173000_10.8.e032552.11","doi-asserted-by":"publisher","DOI":"10.3310\/hta21410"},{"key":"2025101811050173000_10.8.e032552.12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5114\/ada.2016.61599","article-title":"Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases","volume":"33","author":"Wasilewska","year":"2016","journal-title":"Postepy Dermatol Alergol"},{"key":"2025101811050173000_10.8.e032552.13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaut.2016.10.009","article-title":"Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"J Autoimmun"},{"key":"2025101811050173000_10.8.e032552.14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease","year":"2014","journal-title":"Drugs"},{"key":"2025101811050173000_10.8.e032552.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2025101811050173000_10.8.e032552.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"2025101811050173000_10.8.e032552.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.22800"},{"key":"2025101811050173000_10.8.e032552.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401021"},{"key":"2025101811050173000_10.8.e032552.19","doi-asserted-by":"crossref","first-page":"ii49","DOI":"10.1136\/ard.2004.034165","article-title":"Psoriatic arthritis assessment tools in clinical trials","volume":"64 Suppl 2","author":"Mease","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025101811050173000_10.8.e032552.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.051706"},{"key":"2025101811050173000_10.8.e032552.21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.reuma.2017.08.007","article-title":"Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis","volume":"14","author":"Torre Alonso","year":"2018","journal-title":"Reumatol Clin"},{"key":"2025101811050173000_10.8.e032552.22","first-page":"30006","article-title":"Eficacia del secukinumab en psoriasis Y artritis psori\u00e1sica: Estudio multic\u00e9ntrico retrospectivo","volume":"pii:S0025-7753(19)","author":"Ruiz-Villaverde","year":"2019","journal-title":"Med Clin (Barc)"},{"key":"2025101811050173000_10.8.e032552.23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/09546634.2017.1395794","article-title":"Redefining the therapeutic objective in psoriatic patients candidates for biological therapy","volume":"29","author":"Carretero","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"2025101811050173000_10.8.e032552.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.10471"},{"key":"2025101811050173000_10.8.e032552.25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001117"},{"key":"2025101811050173000_10.8.e032552.26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/annrheumdis-2018-eular.2343","article-title":"THU0290\u2005Effects of biologic dmards on physical function in patients with active psoriatic arthritis: results of network meta-analyses","volume":"77","author":"Ruyssen-Witrand","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025101811050173000_10.8.e032552.27","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos . Botplus database, 2018. Available: https:\/\/botplusweb.portalfarma.com\/botplus.aspx [Accessed 22 Mar 2019]."},{"key":"2025101811050173000_10.8.e032552.28","unstructured":"Oblikue Consulting . Base de datos de costes sanitarios espa\u00f1oles: eSalud, 2007. Available: http:\/\/www.oblikue.com\/bddcostes\/ [Accessed 22 Mar 2019]."},{"key":"2025101811050173000_10.8.e032552.29","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X13487257"},{"key":"2025101811050173000_10.8.e032552.30","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13306"},{"key":"2025101811050173000_10.8.e032552.31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key161"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-032552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:05:09Z","timestamp":1760810709000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-032552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,13]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bmjopen-2019-032552"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-032552","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}